Diagnosis and management of autoimmune myasthenia gravis

Clinical Drug Investigation

Volumn 31, Issue 1, 2011, Pages 1-14

  Angelini, Corrado ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

Acetylcholinesterase inhibitors, therapeutic use; Ambenonium chloride, therapeutic use; Azathioprine, therapeutic use; Ciclosporin, therapeutic use; Corticosteroids, therapeutic use; Immune globulin, therapeutic use; Monarsen, therapeutic use; Monoclonal antibodies, therapeutic use; Myasthenia gravis, treatment; Neostigmine, therapeutic use; Plasma exchange; Pyridostigmine, therapeutic use; Research and development; Rituximab, therapeutic use.

Indexed keywords

AMBENONIUM; ANTISENSE OLIGONUCLEOTIDE; AZATHIOPRINE; CD20 ANTIBODY; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EDROPHONIUM; EN 101; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; MONARSEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PHYSOSTIGMINE; PLACEBO; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADD ON THERAPY; ANTISENSE THERAPY; ASYSTOLE; BRADYCARDIA; BRONCHOSPASM; BRONCHUS SECRETION; CLINICAL EVALUATION; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIARRHEA; DISABILITY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; EARLY DIAGNOSIS; ELECTROMYOGRAPHY; GASTROINTESTINAL SYMPTOM; HUMAN; LACRIMATION; LONG TERM CARE; MORTALITY; MYASTHENIA GRAVIS; NAUSEA; NERVE STIMULATION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALIVATION; SEROLOGY; SIDE EFFECT; THYMECTOMY; VOMITING;

CHOLINESTERASE INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, NEUROLOGICAL; MYASTHENIA GRAVIS; THYMECTOMY;

EID: 78149388941     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11584740-000000000-00000     Document Type: Review

References (101)

1. Tiedt TN, Albuquerque EX, Hudson CS, et al. Neostigmineinduced alterations at the mammalian neuromuscular junction. I. Muscle contraction and electrophysiology. J Pharmacol Exp Ther 1978 May; 205 (2): 326-39
2. Boonyapisit K, Kaminski HJ,Ruff RL. Disorders of neuromuscular junction ion channels. Am J Med 1999 Jan; 106 (1): 97-113
3. Hughes BW, Kusner LL, Kaminski HJ. Molecular architecture of the neuromuscular junction.Muscle Nerve 2006 Apr; 33 (4): 445-61
4. Drachman DB. Myasthenia gravis. N Engl J Med 1994 Jun 23; 330 (25): 1797-810
5. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001 Mar; 7 (3): 365-8
6. Witzemann V. Development of the neuromuscular junction. Cell Tissue Res 2006 Nov; 326 (2): 263-71
7. Harper CM. Congenital myasthenic syndromes. Semin Neurol 2004 Mar; 24 (1): 111-23
8. Phillips 2nd LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 1996 Nov; 47 (5): 1233-8
9. Phillips 2nd LH. The epidemiology of myasthenia gravis. Ann N Y Acad Sci 2003 Sep; 998: 407-12
10. Flachenecker P. Epidemiology of neuroimmunological diseases. J Neurol 2006 Sep; 253 Suppl. 5: V2-8
11. Thanvi BR, Lo TC. Update on myasthenia gravis. Postgrad Med J 2004 Dec; 80 (950): 690-700
12. Aarli JA. Myasthenia gravis in the elderly: is it different? Ann N Y Acad Sci 2008; 1132: 238-43
13. Aragones JM, Bolibar I, Bonfill X, et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology 2003 Mar 25; 60 (6): 1024-6
14. Vincent A, Clover L, Buckley C, et al. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003 Aug; 74 (8): 1105-8
15. Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. JNeurol Neurosurg Psychiatry 1989 Oct; 52 (10): 1121-7
16. Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve 2008 Feb; 37 (2): 141-9
17. Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis 2007; 2: 44
18. Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs 2007; 21 (6): 473-81
19. Myasthenia Gravis Foundation of America. Myasthenia gravis: a manual for the health care provider [online]. Available from URL: http: //www.myasthenia.org/docs/MGFA-ProfessionalManual.pdf [Accessed 2008 Nov 18]
20. Barohn RJ, McIntire D, Herbelin L, et al. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998 May 13; 841: 769-72
21. Jaretzki 3rd A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000 Jul 12; 55 (1): 16-23
22. Stewart AL, Hays RD, Ware Jr JE. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988 Jul; 26 (7): 724-35
23. Burns TM, Conaway MR, Cutter GR, et al. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 2008 Aug; 38 (2): 957-63
24. Mullins LL, Carpentier MY, Paul RH, et al. Diseasespecific measure of quality of life for myasthenia gravis. Muscle Nerve 2008 Aug; 38 (2): 947-56
25. Padua L, Evoli A, Aprile I, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 2001 Oct; 22 (5): 363-9
26. Paul RH, Nash JM, Cohen RA, et al. Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 2001 Apr; 24 (4): 512-6
27. Rostedt A, Padua L, Stalberg EV. Correlation between a patient-derived functional questionnaire and abnormal neuromuscular transmission in myasthenia gravis patients. Clin Neurophysiol 2005 Sep; 116 (9): 2058-64
28. Rostedt A, Padua L, Stalberg EV. Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur J Neurol 2006 Feb; 13 (2): 191-3
29. Magni G, Micaglio GF, Lalli R, et al. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand 1988 Apr; 77 (4): 443-5
30. Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol 1997 Feb; 244 (2): 112-8
31. Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis. Clin Immunol Immunopathol 1977 Jan; 7 (1): 36-43
32. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985 Dec; 48 (12): 1246-52
33. Ohta K, Shigemoto K, Kubo S, et al. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology 2004 Jun 8; 62 (11): 2132-3
34. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003 Oct; 126 (Pt 10): 2304-11
35. Shigemoto K, Kubo S, Jie C, et al. Myasthenia gravis experimentally induced with muscle-specific kinase. Ann N Y Acad Sci 2008; 1132: 93-8
36. Martignago S, Fanin M, Albertini E, et al. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol Appl Neurobiol 2009 Feb; 35 (1): 103-10
37. Rostedt Punga A, Ahlqvist K, Bartoccioni E, et al. Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol 2006 Jul; 117 (7): 1434-43
38. Le Panse R, Cizeron-Clairac G, Cuvelier M, et al. Regulatory and pathogenic mechanisms in human autoimmune myasthenia gravis. Ann N Y Acad Sci 2008; 1132: 135-42
39. Scherer K, Bedlack RS, Simel DL. Does this patient have myasthenia gravis? JAMA 2005 Apr 20; 293 (15): 1906-14
40. Bever Jr CT, Aquino AV, Penn AS, et al. Prognosis of ocular myasthenia. Ann Neurol 1983 Nov; 14 (5): 516-9
41. Chaudhuri A, Behan PO. Myasthenic crisis. QJM 2009 Feb; 102 (2): 97-107
42. Panda S, Goyal V, Behari M, et al. Myasthenic crisis: a retrospective study. Neurol India 2004 Dec; 52 (4): 453-6
43. Berrouschot J, Baumann I, Kalischewski P, et al. Therapy of myasthenic crisis. Crit Care Med 1997 Jul; 25 (7): 1228-35
44. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997 Jun; 41 (6): 789-96
45. Murthy JM, Meena AK, Chowdary GV, et al. Myasthenic crisis: clinical features, complications and mortality. Neurol India 2005 Mar; 53 (1): 37-40; discussion 40
46. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007 Mar 13; 68 (11): 837-41
47. Luchanok U, Kaminski HJ. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 2008 Feb; 21 (1): 8-15
48. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 2006 Jul; 16 (7): 459-67
49. Vincent A, Leite MI, Farrugia ME, et al. Myasthenia gravis seronegative for acetylcholine receptor antibodies. Ann N Y Acad Sci 2008; 1132: 84-92
50. Bau V, Hanisch F, Hain B, et al. Ocular involvement in MuSK antibody-positive myasthenia gravis [in German]. Klin Monbl Augenheilkd 2006 Jan; 223 (1): 81-3
51. Cikes N,Momoi MY, Williams CL, et al. Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. Mayo Clin Proc 1988 May; 63 (5): 474-81
52. Dumitru D. Part IV, Section 25: Neuromuscular junction disorders: electrodiagnostic medicine. 2nd ed. Philadelphia (PA): Hanley & Belfus, 2001
53. AAEM Quality Assurance Committee. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve 2001 Sep; 24 (9): 1236-8
54. Howard Jr JF, Sanders DB, Massey JM. The electrodiagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome.NeurolClin 1994May; 12 (2): 305-30
55. Zivkovic SA, Shipe C. Use of repetitive nerve stimulation in the evaluation of neuromuscular junction disorders. Am J Electroneurodiagnostic Technol 2005 Dec; 45 (4): 248-61
56. Stickler DE, Sanders DB. Single-fiber EMG, 2009 [online]. Available from URL: http://emedicine.medscape.com/article/1141438-overview [Accessed 2010 Mar 9]
57. Burns TM, ConawayM, Sanders DB. TheMG composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 2010 May 4; 74 (18): 1434-40
58. Burns TM, Conaway MR, Cutter GR, et al. Construction of an efficient evaluative instrument for myasthenia gravis: theMGcomposite. Muscle Nerve 2008 Dec; 38 (6): 1553-62
59. Genkins G, Sivak M, Tartter PI. Treatment strategies in myasthenia gravis. Ann N Y Acad Sci 1993 Jun 21; 681: 603-8
60. Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet 1934; 1: 1200-1
61. McEachern D. Prostigmine in myasthenia gravis. Can Med Assoc J 1935; 310-1
62. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006 Jul; 13 (7): 691-9
63. Havard CW, Fonseca V. New treatment approaches to myasthenia gravis. Drugs 1990 Jan; 39 (1): 66-73
64. Aquilonius SM, Eckernas SA, Hartvig P, et al. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry 1983 Oct; 46 (10): 929-35
65. Schumm F, Gaertner HJ, Wiatr G, et al. Serum levels of pyridostigmine inmyasthenia gravis: methods and clinical significance [in German]. Fortschr Neurol Psychiatr 1985 Jun; 53 (6): 201-11
66. Osserman KE. Progress report on mestinon bromide (pyridostigmine bromide). Am J Med 1955 Nov; 19 (5): 737-9
67. Data on file, Meda Group, 2010
68. eMC. Mestinon (pyridostigmine bromide) 60mg tablets: summary of product characteristics. 2007 [online]. Available from URL: http://emc.medicines.org.uk/ medicine/865/SPC/Mestinon+60mg+Tablets/ [Accessed 2009May 29]
69. Milner-Brown HS, Mellenthin M, Sharma ML, et al. Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis. Neurology 1987 May; 37 (5): 800-3
70. Young WL, Matteo RS, Ornstein E. Duration of action of neostigmine and pyridostigmine in the elderly. Anesth Analg 1988 Aug; 67 (8): 775-8
71. eMC. Neostigmine bromide tablets: summary of product characteristics. 2001 [online]. Available from URL: http://emc.medicines.org.uk/document.aspx? documentId=384 [Accessed 2009 Apr 6]
72. eMC. Neostigmine methylsulphate BP 2.5mg in 1 mL: summary of product characteristics. 2008 [online]. Available from URL: http://emc.medicines.org.uk/ medicine/20888/SPC/Neostigmine+Methylsulphate+Injection+BP+2.5mg+in+1ml+(hameln) / [Accessed 2009 Jun 2]
73. Schwab RS, Marshall CK, Timberlake W. WIN 8077 in treatment of myasthenia gravis; use of N,N'-bis (2-diethylaminoethyl) oxamide bis-2-chlorobenzyl chloride in fifty patients. J AmMed Assoc 1955 Jun 25; 158 (8): 625-8
74. sanofi-synthelabo. Mytelase® (ambenonium chloride) prescribing information. 2008 July [online]. Available from URL: http://products.sanofi- aventis.us/mytelase/mytelase.html [Accessed 2010 Jun 25]
75. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984 Mar; 15 (3): 291-8
76. Schneider-Gold C, Gajdos P, Toyka KV, et al. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005; (2): CD002828
77. Hart IK, Sharshar T, Sathasivam S. Immunosuppressant drugs for myasthenia gravis. J Neurol Neurosurg Psychiatry 2009 Jan; 80 (1): 5-6; discussion 6
78. Palace J, Newsom-Davis J, Lecky B. A randomized doubleblind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998 Jun; 50 (6): 1778-83
79. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007; (4): CD005224
80. Tindall RS, Rollins JA, Phillips JT, et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987 Mar 19; 316 (12): 719-24
81. Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol 1997 Sep; 244 (9): 542-7
82. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000 May; 47 (2-3): 85-118
83. Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 2003 Nov 25; 61 (10): 1438-40
84. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008 Aug 5; 71 (6): 400-6
85. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008 Aug 5; 71 (6): 394-9
86. Hehir MK, Burns TM, Alpers JP, et al. Long-term experience with mycophenolate mofetil (MMF) in myasthenia gravis (MG): retrospective analysis of 103 patients [abstract]. Neurology 2009; 72 (11 Suppl. 3): A440
87. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. CochraneDatabase Syst Rev 2002; (4): CD002275
88. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008; (1): CD002277
89. Chan A, Lee DH, Linker R, et al. Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol 2007 Nov; 254 (11): 1604-6
90. Hain B, Jordan K, Deschauer M, et al. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006 Apr; 33 (4): 575-80
91. Thakre M, Inshasi J, Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 2007 Jul; 254 (7): 968-9
92. Sussman JD, Argov Z, McKee D, et al. Antisense treatment for myasthenia gravis: experience with monarsen. Ann N Y Acad Sci 2008; 1132: 283-90
93. Gronseth GS, Barohn RJ. Thymectomy for myasthenia gravis. Curr Treat Options Neurol 2002 May; 4 (3): 203-9
94. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000 Jul 12; 55 (1): 7-15
95. Aghajanzadeh M, Khoshrang H, Mohammadzadeh A, et al. Thymectomy for myasthenia gravis: prognostic factors in 70 patients. Asian Cardiovasc Thorac Ann 2007 Oct; 15 (5): 371-5
96. Abt PL, Patel HJ, Marsh A, et al. Analysis of thymectomy for myasthenia gravis in older patients: a 20-year single institution experience. J Am Coll Surg 2001 Apr; 192 (4): 459-64
97. Tsuchida M, Yamato Y, Souma T, et al. Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis. Ann Thorac Surg 1999 Jun; 67 (6): 1563-7
98. Sanders DB, El-Salem K, Massey JM, et al. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003 Jun 24; 60 (12): 1978-80
99. Magee MJ, Mack MJ. Surgical approaches to the thymus in patients with myasthenia gravis. Thorac Surg Clin 2009 Feb; 19 (1): 83-9, vii
100. Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a US experience. Muscle Nerve 2010 Mar; 41 (3): 370-4
101. ClinicalTrials.gov. Thymectomy trial in non-thymomatous myasthenia gravis patients receiving prednisone therapy. 2009 November 9 [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00294658?term=non- thymomatous&rank=1 [Accessed 2010 Jun 25]